A critical challenge in myelofibrosis care is that the optimal time for a curative transplant is when patients feel well, often due to effective JAK inhibitor therapy. This feeling of well-being makes them reluctant to undergo the high-risk procedure. Waiting until they feel sick makes the transplant less likely to succeed.
A patient's risk score primarily determines their candidacy for a stem cell transplant. However, the decision to start a JAK inhibitor is driven by symptoms like splenomegaly and constitutional issues, regardless of the patient's formal risk status. This decouples two key treatment decisions.
Recent Phase 3 trials for novel myelofibrosis combinations (e.g., pelabrasib or selinexor with ruxolitinib) show a consistent pattern. They successfully reduce spleen volume but fail to demonstrate a statistically significant improvement in patient-reported symptom scores compared to ruxolitinib alone, questioning the link between these two endpoints.
A proactive clinical practice is to refer all newly diagnosed myelofibrosis patients for a transplant consultation, irrespective of their initial risk score. This preemptive step helps overcome significant logistical delays in finding a suitable donor, which is particularly crucial for patients from diverse ethnic backgrounds where donor availability is limited.
The anemia seen in myelofibrosis patients on ruxolitinib is not just a drug side effect but an interaction with the underlying disease. This is proven by the fact that polycythemia vera patients on the same drug do not become anemic, showing the myelofibrotic marrow is uniquely susceptible to the drug's effects.
Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.